EP2049085A1 - Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant - Google Patents
Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenantInfo
- Publication number
- EP2049085A1 EP2049085A1 EP07801468A EP07801468A EP2049085A1 EP 2049085 A1 EP2049085 A1 EP 2049085A1 EP 07801468 A EP07801468 A EP 07801468A EP 07801468 A EP07801468 A EP 07801468A EP 2049085 A1 EP2049085 A1 EP 2049085A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- microparticles
- group
- polymer
- suspension
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011859 microparticle Substances 0.000 title claims abstract description 160
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 239000004480 active ingredient Substances 0.000 title claims abstract description 8
- 229920001577 copolymer Polymers 0.000 title claims description 21
- 239000000203 mixture Substances 0.000 claims abstract description 127
- 239000000725 suspension Substances 0.000 claims abstract description 98
- 238000009472 formulation Methods 0.000 claims abstract description 82
- 238000000889 atomisation Methods 0.000 claims abstract description 65
- 239000006185 dispersion Substances 0.000 claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000002253 acid Substances 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 46
- 239000002105 nanoparticle Substances 0.000 claims abstract description 26
- 229920001308 poly(aminoacid) Polymers 0.000 claims abstract description 21
- 239000007787 solid Substances 0.000 claims abstract description 16
- 229920000642 polymer Polymers 0.000 claims description 197
- 239000007788 liquid Substances 0.000 claims description 64
- 239000002245 particle Substances 0.000 claims description 53
- 239000000843 powder Substances 0.000 claims description 48
- 238000012360 testing method Methods 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 37
- 150000001768 cations Chemical class 0.000 claims description 30
- 150000002433 hydrophilic molecules Chemical class 0.000 claims description 28
- -1 poly-N-vinylamides Polymers 0.000 claims description 28
- 150000002500 ions Chemical class 0.000 claims description 27
- 125000001165 hydrophobic group Chemical group 0.000 claims description 26
- 239000012071 phase Substances 0.000 claims description 23
- 239000011248 coating agent Substances 0.000 claims description 21
- 238000000576 coating method Methods 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 21
- 230000002209 hydrophobic effect Effects 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 229940024606 amino acid Drugs 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 239000012074 organic phase Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 239000012730 sustained-release form Substances 0.000 claims description 12
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 11
- 239000011777 magnesium Substances 0.000 claims description 11
- 229920000136 polysorbate Polymers 0.000 claims description 11
- 238000013268 sustained release Methods 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 7
- 150000003626 triacylglycerols Chemical class 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000008158 vegetable oil Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 229920000768 polyamine Polymers 0.000 claims description 6
- 230000002685 pulmonary effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 229920002873 Polyethylenimine Polymers 0.000 claims description 5
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 5
- 108010039918 Polylysine Proteins 0.000 claims description 5
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 5
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 5
- 229920001519 homopolymer Polymers 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 150000002892 organic cations Chemical class 0.000 claims description 5
- 229920000656 polylysine Polymers 0.000 claims description 5
- 229950008882 polysorbate Drugs 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000002334 glycols Chemical class 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 235000019486 Sunflower oil Nutrition 0.000 claims description 3
- 229920013820 alkyl cellulose Polymers 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 239000003240 coconut oil Substances 0.000 claims description 3
- 235000019864 coconut oil Nutrition 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000944 linseed oil Substances 0.000 claims description 3
- 235000021388 linseed oil Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 239000008159 sesame oil Substances 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000002600 sunflower oil Substances 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 150000003951 lactams Chemical class 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229950003429 sorbitan palmitate Drugs 0.000 claims description 2
- 229950011392 sorbitan stearate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 47
- 108090000623 proteins and genes Proteins 0.000 abstract description 47
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 20
- 230000002776 aggregation Effects 0.000 abstract description 11
- 238000004220 aggregation Methods 0.000 abstract description 11
- 239000012669 liquid formulation Substances 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 93
- 235000018102 proteins Nutrition 0.000 description 46
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 29
- 102000018997 Growth Hormone Human genes 0.000 description 26
- 108010051696 Growth Hormone Proteins 0.000 description 26
- 239000000122 growth hormone Substances 0.000 description 26
- 230000001225 therapeutic effect Effects 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 229920001983 poloxamer Polymers 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000004094 surface-active agent Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000002035 prolonged effect Effects 0.000 description 10
- 108010057186 Insulin Glargine Proteins 0.000 description 9
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229940060975 lantus Drugs 0.000 description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 108010000521 Human Growth Hormone Proteins 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 229940049906 glutamate Drugs 0.000 description 5
- 238000003760 magnetic stirring Methods 0.000 description 5
- 229960000502 poloxamer Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 108700012941 GNRH1 Proteins 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012470 diluted sample Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 210000004417 patella Anatomy 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000010415 colloidal nanoparticle Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 229960002869 insulin glargine Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920006030 multiblock copolymer Polymers 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000011164 primary particle Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 229920005604 random copolymer Polymers 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010012944 Tetragastrin Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010076164 Tyrocidine Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000002871 fertility agent Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011090 industrial biotechnology method and process Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940127560 insulin pen Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- GSXRBRIWJGAPDU-BBVRJQLQSA-N tyrocidine A Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 GSXRBRIWJGAPDU-BBVRJQLQSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 125000001020 α-tocopherol group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Definitions
- the present invention relates to novel transporters of the active principle (s) -PA-, in particular protein (s) and peptide (s), as well as new modified-release pharmaceutical formulations containing said transporters of PA.
- the therapeutic applications (human and veterinary) of these formulations are numerous.
- the PA reference used throughout this disclosure is directed to at least one active ingredient.
- modified release is meant a prolonged or delayed or pulsatile release.
- novel PA transporters to which the invention relates are microparticles of amphiphilic polymers, for example polyamino acids modified with hydrophobic groups. These microparticles contain at least one PA associated with the polymer and may be in the form of colloidal suspensions or in dry form.
- the plasma concentration of therapeutic protein then has a sawtooth profile, characterized by high concentration peaks and very low concentration minima. Concentration peaks, much higher than the basal concentration in healthy subjects, have very significant adverse effects due to the high toxicity of therapeutic proteins such as interleukin IL-2. In addition, the concentration minima are lower than the concentration required to have a therapeutic effect, which leads to poor therapeutic coverage of the patient and serious consequences in the long term.
- sustained-release forms of therapeutic protein consisting of suspensions, liquid and low viscosity, of nanoparticles. particles loaded with therapeutic proteins. These suspensions allowed the easy administration of native therapeutic proteins.
- the therapeutic protein has been associated with nanoparticles of a copolyamino acid comprising hydrophobic groups and hydrophilic groups.
- US-B-5,904,936 discloses submicron particles (NPV) - average size between 0.01 and 0.5 microns - and micrometric particles (micron) (MPV) - average size between 0.5 and 20 ⁇ m - of amphiphilic copolymer of polyamino acids comprising at least two types of amino acids, one being hydrophilic neutral, the other being ionizable. Proteins such as insulin adsorb spontaneously in aqueous solution to these particles.
- the polyamino acid copolymer is, for example, a block copolymer of sodium poly (L-leucine-bL-glutamate).
- This patent describes the aggregation of NPV in MPV by addition to a colloidal suspension of poly-Leu / Glu of monocation salts (ammonium sulfate), polycationic (Fe 2+ , Fe 3+ , Zn 2+ , Ca 2+ , Al 2+ , Al 3+ or Cu 2+ ), acid (HCl) or cationic polymers (polylysine).
- the patent application WO-A-03/104303 discloses amphiphilic polyamino acids comprising aspartic residues or glutamic residues, at least a portion of these residues carrying grafting agents comprising at least one alpha-tocopherol unit (for example: polyglutamate or polyaspartate grafted with alpha tocopherol of synthetic or natural origin).
- grafting agents comprising at least one alpha-tocopherol unit (for example: polyglutamate or polyaspartate grafted with alpha tocopherol of synthetic or natural origin).
- alpha-tocopherol unit for example: polyglutamate or polyaspartate grafted with alpha tocopherol of synthetic or natural origin.
- the in vivo release time of the active protein (s) (e.g., insulin) vectorized by the suspensions according to US-B-5,904,936 or WO-A-2003/104303 would benefit from being increased.
- the increase in the release time has been partially achieved by the pharmaceutical forms disclosed in PCT application WO-A-05/051416.
- the protein is then slowly released over a period of typically one week.
- the therapeutic protein concentration to be administered is relatively high, as is the case for example for human growth hormone, the release time is limited to a few days only.
- PAs eg proteins, therapeutic peptides and small molecules
- multivalent ions such as Mg 2+ , Ca 2+ , Zn 2+ , Fe 2+ , Cu 2+ or mixtures thereof or Al 3+ , Fe 3+ or mixtures thereof, confer excellent tolerance to such a liquid pharmaceutical formulation for prolonged release of AP.
- n is the valence of said multivalent ions
- [IM] is the molar concentration of multivalent ions
- - [GI] is the molar concentration of ionizable groups GI
- micrometric particles are derived from the aggregation of a large number of amphiphilic copolymer nanoparticles.
- a suspension of microparticles loaded with PA (for example hGH) can thus be manufactured by flocculation with multivalent ions Mg 2+ , Ca 2+ , Zn 2+ , Fe 2+ , Cu 2+ Al 3+ or Fe 3+ , this flocculation being followed by maturation and washing.
- the suspension can then be lyophilized or atomized and then reconstituted with water to make a formulation ready to inject.
- this reconstituted suspension can be easily injected by passage through a hollow needle associated with a syringe or an injection pen (insulin pen type).
- an injection pen insulin pen type
- one of the essential objectives of the invention would be to propose new microparticles obtained by aggregation of amphiphilic polymer nanoparticles, biodegradable and water-soluble, for example of the type according to the formulation described in WO-A-05. / 051416, these microparticles being loaded with PA and having vocation to have improved properties, especially in dry solid form, in particular with regard to their dispersibility (or dispersibility), and, as regards the reconstituted suspension, its stability and its ability to be easily manipulated and injected.
- Another objective of the invention is to propose novel microparticles obtained by aggregation of amphiphilic, biodegradable and water-soluble amphiphilic polymer nanoparticles, said microparticles being loaded with PA and having good properties. dispersion whether in aqueous or organic phase, while maintaining the integrity of said microparticles.
- Another object of the invention is to provide novel microparticles obtained by aggregation of amphiphilic polymer bioparticles, biodegradable and water-soluble, said microparticles being loaded with PA and having excellent stability properties in solid and dry form.
- Another objective of the invention is to propose a new process for the preparation of microparticles in solid and dry form, these microparticles being moreover:
- biodegradable and water-soluble amphiphilic polymer nanoparticles Obtained by aggregation of biodegradable and water-soluble amphiphilic polymer nanoparticles, for example of the type of those according to the formulation described in WO-A-05/051416;
- Another object of the invention is to provide a method for preparing microparticles in solid and dry form, of the type referred to in the previous objective and which is otherwise simple, economic and industrial.
- Another object of the invention is to provide a pharmaceutical formulation comprising novel microparticles obtained by aggregation of amphiphilic polymer nanoparticles, biodegradable and water-soluble, for example of the type according to the formulation described in WO-A-03/104303, these microparticles being otherwise:
- Another object of the invention is to provide a pharmaceutical formulation for the sustained release of PA, remedying deficiencies of the prior art, and in particular allowing after parenteral injection (eg subcutaneous) to obtain a prolonged in vivo release of PA (eg, proteins, therapeutic peptides or small molecules) undenatured.
- Another object of the invention is to provide a pharmaceutical formulation allowing, after parenteral injection (eg subcutaneous), to obtain a prolonged in vivo release time of highly concentrated therapeutic proteins or peptides, for example at several mg / ml.
- Another object of the invention is to provide a sustained-release pharmaceutical formulation of PA in vivo, which is stable to conservation both physico-chemical and biological.
- Another object of the invention is to provide a sustained-release pharmaceutical formulation of PA in vivo, which has at least one of the following properties: biocompatibility, biodegradability, non-toxicity, good local tolerance.
- Another object of the invention is to provide a pharmaceutical formulation for the slow sustained release of PA in vivo, comprising microparticles of amphiphilic PO polymer self-associated with at least one PA (PO / PA microparticles), the PO polymer being a biodegradable, water-soluble polymer carrying hydrophobic groups (GH) and hydrophilic groups (preferably ionizable (GI) at least in part) ionized) forming spontaneously in water a suspension of colloidal nanoparticles, this PO polymer being, for example, a polyamino acid whose main chain is formed by aspartic residues or glutamic residues, at least a portion of these residues being modified by grafting at least one hydrophobic group GH, in the chain or at the end of the chain.
- GH hydrophobic groups
- GI ionizable
- Another objective of the invention is to propose a kit for reconstituting the formulation as defined in the above-mentioned objectives, this kit being for example simple to use, so that it can be easily implemented by the patient or by the medical staff.
- Another object of the invention is to provide a method for reconstituting the formulation as defined in the above-mentioned objectives, this method being for example simple to implement in particular by the patient or the medical staff.
- Another object of the invention is to provide a solid pharmaceutical formulation for the sustained release of PA, in particular a dry powder form for inhalation and pulmonary administration:
- the inventors have had the merit of discovering, after long and laborious research, that, quite surprisingly and unexpectedly, the atomization of formulations based on amphiphilic PO (for example of copolyamino acids) and PA leads to very stable, dry PO / PA microparticles, making it possible to reconstitute aqueous suspensions of microparticles in a liquid medium whose size is between 0.5 and 100 ⁇ m.
- the inventors have had the merit of developing means for reconstituting a suspension from these microparticles, said means making it possible to optimize their dispersion both in the aqueous liquid phase and in the organic liquid phase.
- Atomization is a known industrial technique for obtaining dry particles from a solution or suspension of the constituent material of said particles.
- the atomization or spray drying is to evaporate very quickly in a stream of air or hot inert gas nebulized droplets of this solution or suspension.
- the atomization can be delicate because it imposes a thermal stress which may be prohibitive for certain heat-sensitive PAs such as PAs based on proteins or other peptide compounds.
- the use of atomization to produce dry particles based excipients and PA is not therefore obvious, except to select excipients capable of preventing or minimizing the denaturation of PA peptides.
- the application US-A-2005/0158392 discloses the preparation of lipophilic solid microparticles loaded with peptide PA by atomization.
- the latter consists either in atomizing an aqueous solution containing hyaluronic acid, PA and a lipophilic surfactant (eg lecithin) or even another surfactant of Tween 80 type; either, in a first step, atomizing an aqueous solution containing hyaluronic acid, PA and optionally a surfactant like Tween ® 80 to obtain primary particles, and, secondly, atomizing an alcoholic solution of lipophilic surfactant (eg lecithin) in which the primary particles are dispersed.
- a lipophilic surfactant eg lecithin
- hyaluronic acid and lipophilic surfactant eg lecithin
- hyaluronic acid and lipophilic surfactant eg lecithin
- amphiphilic POs and even less amphiphilic copolyamino acids as excipients or carriers of PA together forming the microparticles.
- amphiphilic POs and even less amphiphilic copolyamino acids as excipients or carriers of PA together forming the microparticles.
- Another example of atomization is that described in the article Maa et al, J Pharm
- PA human growth hormone
- microparticles being characterized: a. in that they are obtained by atomization of a solution or a colloidal suspension of PO comprising at least one PA, b. by a size, measured in a T test, between 0.5 and 100 ⁇ m, preferably between 1 and 70 ⁇ m, preferably between 2 and 40 ⁇ m, c. and in that they are dispersible in colloidal suspension in a DPl dispersibility test.
- the invention relates to a process for preparing microparticles of polymer PO associated with at least one active principle (PA), these microparticles PO / PA being in particular those defined above according to the first aspect of the invention.
- PA active principle
- microparticles having a size, measured in a T test, between 0.5 and 100 ⁇ m, preferably between 1 and 70 ⁇ m, preferably between 2 and 40 ⁇ m, characterized in that it consists essentially in atomizing a solution or a colloidal suspension of PO containing PA.
- the microparticles obtained by atomization are redispersed in a substantially aqueous liquid medium (preferably comprising multivalent ions as dispersing means) and then the dispersion obtained is freeze-dried.
- a substantially aqueous liquid medium preferably comprising multivalent ions as dispersing means
- the invention in a third aspect, relates to a liquid pharmaceutical formulation for the sustained release of PA, characterized in that it comprises a low viscosity colloidal suspension based on PO microparticles, containing at least minus one PA, these microparticles being those defined above according to the first aspect of the invention or those obtained by the process defined above according to the second aspect of the invention.
- the invention relates to a reconstitution kit in particular of the formulation as defined above according to a third aspect of the invention, characterized in that it comprises:
- Microparticles of PO containing at least one AP are those defined above according to the first aspect of the invention or those obtained by the process defined above according to the second aspect of the invention;
- the invention relates to a method of reconstitution, in particular of the formulation as defined above according to a third aspect of the invention, characterized in that it consists essentially of:
- the invention relates to a solid pharmaceutical formulation for the sustained release of PA, characterized in that it comprises a dry powder form for inhalation and pulmonary administration:
- microparticles of PO containing at least one PA Based on microparticles of PO containing at least one PA, these microparticles being those defined above according to the first aspect of the invention or those obtained by the process defined above according to the second aspect of the invention;
- hydrophobic groups of the PO polymers which can assemble into hydrophobic domains, play an important role in the PA modified release process, as well as in the stabilization of the latter. .
- the affinity of the protein for the PO polymer makes it possible to limit the protein aggregation phenomena and other degradations that may occur during the atomization process, without the need to resort to other stabilizers (eg sugars, surfactants).
- This protective effect of PO also makes it easy to obtain storage-stable liquid formulations.
- the PO when it has an essentially amorphous character (especially when it is a polyamino acid), gives the microparticles excellent properties of physical stability when they are kept in dry form.
- amphiphilic PO polyamino acids provides additional levers for the modified release of the PA as well as for its stabilization with respect to aggregation or possible chemical degradation.
- amphiphilic nature of the PO polymer makes it possible, during the atomization process, to be able to use either an entirely aqueous phase, or a fully volatile organic phase, or a volatile mixture of aqueous and organic phase, which offers great flexibility in the implementation of the method.
- microparticles formed from a (co) polyamino acid type PO are biodegradable, biocompatible and generally have good local tolerance properties.
- microparticles according to the invention namely the atomization
- the microparticles according to the invention and the formulations containing them are non-toxic and well tolerated locally.
- a linear alkyl which may include at least one heteroatom (O, N or S) or at least one unsaturation may have two heteroatoms, N and S, and unsaturation.
- the term “submicronic particles” or “nanoparticles” designates particles of size (measured in a T test described below), greater than or equal to 1 nm and less than 500 nm, preferably between 5 and 250 nm.
- the term “polyamino acid” covers both natural polyamino acids and synthetic polyamino acids, as well as oligoamino acids comprising from 10 to 20 amino acid residues in the same way as polyamino acids comprising more than 20 amino acid residues.
- the preferred amino acid residues of the main polyamino acid chain are those having the L configuration; the preferred type of binding is the alpha type, i.e., a peptide bond between an alpha-amino group of an amino acid and the carboxyl group at the 1-position of another alpha-amino acid.
- protein designates, for example, a protein as well as a peptide, whether it be an oligo or a polypeptide.
- This protein (or this peptide) can be modified or not, for example, by grafting one or more polyoxyethylene groups.
- association For the purposes of the invention and throughout this presentation, the terms "association" or
- "associate" employees to qualify the relationship between one or more PA and PO polymers mean in particular that the active ingredient (s) are bound to the polymer (s) PO by a non-covalent bond, for example by electrostatic or hydrophobic interaction or hydrogen bond or steric hindrance.
- the bactericidal microparticles (a) the bactericidal microparticles (a);
- the PA for example a protein or another peptide compound
- an amphiphilic PO polymer such as a (co) polyamino acid amphiphilic
- the physical atomization treatment confers on the solid dry microparticles obtained a particular structure at the origin of many of their advantageous properties. This structure is correctly characterized by this method of obtaining by atomization, as well as by the functions attached to these advantageous properties.
- Characteristic (b) This characteristic is defined objectively by the T test described below. T test for measuring the size of the microparticles by laser diffraction:
- the circulating fluid stored in the dispersion system liquid channel at rest is drained and replaced with heptane.
- the agitation of the Hydro 2000SM module is positioned at 2400 rpm.
- Data on the D50 is obtained, which is the diameter below which 50% of the objects analyzed are found.
- the sample to be analyzed is introduced into the cell as it is or may optionally be rediluted by water in the case of highly diffusing samples. 3 Analysis of the sample
- the circulating fluid stored in the liquid dispersion system at rest is drained and replaced with fresh demineralized water.
- the agitation of the Hydro 2000SM module is positioned at 2400 rpm.
- Data on the D50 is obtained, which is the diameter below which 50% of the objects analyzed are found.
- test sample 400 ⁇ L of the test sample should be diluted in a 5 mL test tube with 600 ⁇ L of heptane and vortexed for 10 ⁇ 5 s.
- the circulating fluid stored in the dispersion system liquid channel at rest is drained and replaced with heptane.
- the agitation of the Hydro 2000SM module is positioned at 2400 rpm.
- the entire suspension is aspirated through a 1 ml syringe (Braun Injeckt-F Luer type 1 ml - ref 9166017V) equipped with a 25G needle and transferred to a new vial beforehand. calibrated and the mass m 3 of solution recovered is determined.
- the powder has good dispersion properties in the liquid if: the suspension obtained contains microparticles with a mean diameter of between 2 and 40 ⁇ m, the appearance of the suspension is homogeneous, it can be injected through a needle 25G and if - at least 80% of the suspension can be recovered.
- microparticles according to the invention can be defined objectively by the fact that they are stable in an ST1 test or in an ST2 test.
- the size of the microparticles present in the atomized dry powder is measured in the week following the atomization of the powder on a laser granulometer according to the TO test.
- the powder is then placed in an oven at 30 ° C for one week.
- a control sample is left at 5 ° C.
- a measurement of size is carried out again after dispersion under the same conditions as time tO. The particle distributions before and after aging are compared.
- the microparticle powder is dispersed in the dispersion liquid with magnetic stirring at the concentration at which it is desired to observe its stability and is allowed to stir with moderate magnetic stirring for at least 2 hours (measurement t0).
- the size of the particles is measured on a laser granulometer according to the Tl or T2 test depending on the medium (aqueous or organic) dispersion.
- the suspension is then allowed to stand for 7 days at 5 ° C.
- the sedimentation pellet is dispersed by stirring for a few minutes (until a homogeneous suspension is obtained after visual observation).
- a measurement of size is carried out again after dispersion under the same conditions as time tO.
- the PO polymers according to the invention are biodegradable, water-soluble polymers carrying hydrophobic groups GH and groups hydrophilic (preferably ionizable GI groups, at least partially ionized).
- the hydrophobic groups GH may be in reduced number vis-à-vis the rest of the chain and may be located laterally to the chain or interspersed in the chain, and be randomly distributed (random copolymer) or distributed in the form of sequences or grafts (block copolymers or block copolymers).
- the PO polymer is an amphiphilic (co) polyamino acid.
- Such a choice of PO provides excellent compatibility with PAs of the protein (s) / peptide (s) type. It is thus possible to greatly simplify the composition of the starting solution or suspension of the protein (s) / peptide (PA) -type PA with the PO polymer.
- This starting solution or suspension may comprise only PA and PO in an aqueous or organic phase. The absence of other ingredients allows such a solution or starting suspension can be filtered (pore size: 0.2 microns) before atomization, which allows the latter to be carried out under aseptic conditions.
- the PO is chosen from the
- the polyamino acids according to the present invention are oligomers or homopolymers comprising recurring glutamic or aspartic acid residues or copolymers comprising a mixture of these two types of residues.
- the residues considered in these polymers are amino acids having the D, L or D / L configuration and are linked by their alpha or gamma positions for the glutamate or glutamic residue and alpha or beta for the aspartic or aspartate residue.
- the polymer PO is a polyamino acid formed by aspartic residues or glutamic residues, at least a portion of these residues carrying scions comprising at least one hydrophobic group GH.
- These polyamino acids are in particular of the type described in PCT patent application WO-A-00/30618.
- the (or) PO is (are) set (s) by the formula ggéénnéérraallee ((II)) ssuuiivvaannttee ((tthhee rraaddiiccaall - CCOOOORR 33 i includes forms wherein the bond between the carboxyl and R 3 is an ionic bond - COO "+ R 3 ):
- R 1 is selected from the group consisting of H, linear C2 to C 10 alkyl, branched C 3 -C 10, benzyl, and -R 4 - [GH], or "NHR 1 is a terminal amino acid residue;
- R 2 is selected from the group consisting of H, C 2 -C 10 linear acyl, C 3 -C 10 branched acyl, and -R 4 - [GH] or "R 2 is a terminal pyroglutamate residue;
- R + is preferably selected from the group comprising: metal cations advantageously chosen from the subgroup comprising: sodium, potassium, calcium, magnesium, organic cations advantageously chosen from the subgroup comprising:
- the cations based on amino acid (s) advantageously chosen from the class comprising cations based on lysine or arginine, or cationic polyamino acids advantageously chosen from the subgroup comprising polylysine or oligolysine ;
- R 4 represents a direct bond or a spacer based on 1 to 4 amino acid residues
- A is independently -CH 2 - (aspartic residue) or - CH 2 -CH 2 - (glutamic residue);
- GH is selected from the group consisting of alkoxy radicals of the type: OCH 2 (CH 2 -CH 2 ) 3 g -CH 3 , oleyl, tocopheryl or cholesteryl, and R 4 represents a single valence bond.
- GH represents a hydrophobic group having 6 to 30 carbon atoms
- R 30 is a C2-CO bivalent linear alkylene chain;
- R 3 ' is H, or "1 H 3' is preferably selected from the group consisting of:
- the metal cations advantageously chosen from the subgroup comprising: sodium, potassium, calcium, magnesium, the organic cations advantageously chosen from the subgroup comprising:
- cations based on amino acid (s) advantageously chosen from the class comprising cations based on lysine or arginine,
- R 50 is a C1 to C8 divalent linear alkylene chain in which one or two methylenes, preferably at each end of R 50 , may be independently replaced by -O- or -NH-;
- R 4 represents a direct bond or a spacer based on 1 to 4 amino acid residues
- A independently represents a radical -CH 2 - (aspartic residue) or -CH 2 - CH 2 - (glutamic residue);
- n '+ m' or n " is defined as the degree of polymerization and varies from 10 to 1000, preferably between 50 and 300.
- R 4 represents a simple valence bond.
- PO comprises at least one essentially neutral copolyhydroxyalkylglutamine (preferably alkyl is ethyl) comprising a multiplicity of pendant hydrophobic groups (GH), which are identical or different from each other.
- the copolyhydroxyalkylglutamine carries hydroxyalkylamino groups. These hydroxyalkylamino groups are preferably bonded to the copolymer via an amide bond.
- hydroxyalkylamines that can be used to amidify the carboxyl of glutamate residues and to give this copolyhydroxyalkylglutamine are identical or different from each other and are, for example, chosen from 2-hydroxyethylamine, 3-hydroxypropylamine, 2,3-dihydroxypropylamine, tris (hydroxymethyl) aminomethane and 6-hydroxyhexylamine.
- At least one of the hydrophobic groups GH is included in a hydrophobic graft comprising at least one patella (or pattern) spacing (spacer) for connecting the hydrophobic group GH to a main chain of copolyglutamates.
- This patella may comprise, e.g. at least one direct covalent bond or at least one amide bond or at least one ester bond.
- the patella may be of the type belonging to the group comprising in particular: residues amino acids, aminoalcohol derivatives, polyamine derivatives (eg diamines), polyol derivatives (eg diols) and hydroxy acid derivatives.
- the grafting of the GH on the copolyglutamate or polyhydroxyalkylglutamine chain can be carried out by the use of precursors of GH, able to bind to the copolyglutamate or copolyhydroxyalkylglutamine chain.
- the precursors of GH are, in practice and without being limited to, selected from the group comprising alcohols and amines, these compounds being easily functionalized by those skilled in the art.
- this copolhydroxyalkylglutamine preferably alkyl is ethyl
- all or part of the hydrophobic radicals GH of the POs are independently selected from the group of radicals comprising: a linear or branched alkoxy having from 6 to 30 atoms of carbon and may comprise at least one heteroatom (preferably O, N or S) or at least one unsaturation,
- alkoxy having 6 to 30 carbon atoms and having one or more annealed cycloalkyls and optionally containing at least one unsaturation or at least one heteroatom (preferably O, N or S),
- the hydrophobic group GH is chosen from the group comprising the alkoxy radicals of the type: OCH 2 (CH 2 -CH 2 ) 3 g -CH 3 , oleyl, tocopheryl or cholesteryl, and R 4 represents a single valence bond.
- n GH groups of the PO in particular according to at least one of the three aforementioned contingencies, each independently represent a monovalent radical of the following formula:
- R 5 is methyl (alanine residue), isopropyl (valine), isobutyl (leucine), secbutyl (isoleucine), benzyl (phenylalanine);
- R 6 represents a hydrophobic radical containing from 6 to 30 carbon atoms
- - 1 varies from 0 to 6.
- all or part of the hydrophobic radicals R 6 of the PO are independently selected from the group of radicals comprising: a linear or branched alkoxy having from 6 to 30 carbon atoms and which may comprise at least minus one heteroatom (preferably O, N or S) or at least one unsaturation,
- alkoxy having 6 to 30 carbon atoms and having one or more annealed cycloalkyls and optionally containing at least one unsaturation or at least one heteroatom (preferably O, N or S),
- the hydrophobic radical R 6 of the PO graft is chosen from the group comprising the alkoxy radicals of the type: OCH 2 (CH 2 -CH 2 ) 3 g -CH 3 , oleyl, tocopheryl or cholesteryl.
- the main chain of the polyamino acid is: a homopolymer of alpha-L-glutamate or alpha-L-glutamic acid; a homopolymer of alpha-L-aspartate or alpha-L-aspartic acid
- the distribution of the aspartic or glutamic residues of the main polyamino acid chain of the PO is such that the polymer thus constituted is either random, or of the block type, or of the multiblock type.
- PO has a molar mass which is between 2,000 and 100,000 g / mol, and preferably between 5,000 and 40,000 g / mol.
- PO carries at least one graft of polyalkylene glycol type bound to a glutamate or aspartate residue.
- this graft is of polyalkylene glycol type is of formula (V) below.
- X is a heteroatom selected from the group consisting of oxygen, nitrogen or sulfur;
- R 7 and R 8 independently represent H, linear C 1 -C 4 alkyl
- the polyalkylene glycol is for example a polyethylene glycol.
- the molar percentage of grafting of the polyalkylene glycol ranges from 1 to 30%.
- PA active principles such as proteins, peptides or small molecules can spontaneously associate with PO polyamino acid nanoparticles.
- POs contain ionizable groups which are, depending on the pH and the composition, either neutral (for example -COOH) or ionized (for example -COO " ).
- the solubility in one phase Aqueous solution is directly a function of the fraction of ionized functions and therefore of the pH
- the counterion may be a metal cation such as sodium, calcium or magnesium, or an organic cation such as the protonated forms of triethanolamine, tris (hydroxymethyl) aminomethane or a polyamine such as polyethyleneimine.
- PO polyamino acid type are obtained, for example, by methods known to those skilled in the art.
- the random polyamino acids can be obtained by grafting the hydrophobic graft, previously functionalized by the spacer, directly onto the polymer by a conventional coupling reaction.
- the block or multiblock polyamino acid POs can be obtained by sequential polymerization of the corresponding N-carboxy-amino acid anhydrides (NCA).
- a polyamino acid, homopolyglutamate, homopolyaspartate or a glutamate / aspartate, block, multiblock or random copolymer is prepared according to conventional methods.
- NCA N-carboxy-amino acid anhydrides
- polymers usable according to the invention for example of the poly (alpha-L-aspartic), poly (alpha-L-glutamic), poly (alpha-D-glutamic) and poly (gamma-L-glutamic) type variable masses are commercially available.
- Alpha-beta polyaspartic acid is obtained by condensation of aspartic acid (to obtain polysuccinimide) followed by basic hydrolysis (see Tomida et al., Polymer, 1997, 18:
- Coupling of the graft with an acidic function of the polymer is easily achieved by reaction of the polyamino acid in the presence of a carbodiimide as coupling agent and optionally a catalyst such as 4-dimethylaminopyridine and in a suitable solvent such as dimethylformamide (DMF) N-methylpyrrolidone (NMP) or dimethylsulfoxide (DMSO).
- a carbodiimide is, for example, dicyclohexylcarbodiimide or diisopropylcarbodiimide.
- the degree of grafting is chemically controlled by the stoichiometry of the constituents and reactants or the reaction time. Hydrophobic grafts functionalized by a spacer are obtained by conventional peptide coupling or by direct condensation by acid catalysis. These techniques are well known to those skilled in the art.
- NCA derivatives previously synthesized with the hydrophobic graft are used.
- the NCA-hydrophobic derivative is copolymerized with the NCA-O-Bz and then the benzyl groups are selectively removed by hydrolysis.
- PA it is preferably chosen from the group comprising: proteins, glycoproteins, proteins linked to one or more polyalkylene glycol chains [preferably polyethylene glycol (PEG): “PEGylated proteins”], peptides, polysaccharides, liposaccharides, oligonucleotides, polynucleotides and mixtures thereof, and, more preferably still, in the subgroup of erythropoietin, oxytocin, vasopressin, adrenocorticotropic hormone, epidermal growth factor, platelet growth factor (PDGF), hematopoietic growth factors and their mixtures, factors VIII and IX, hemoglobins, cytochromes , albumin, prolactin, luteinizing hormone releasing hormone (LHRH), LHRH antagonists, LHRH agonists, human growth hormone (GH), porcine or bovine, growth hormone releasing hormone, insulin , somatostatin, glucagon, interleukins or their
- PA is a small hydrophobic, hydrophilic or amphiphilic organic molecule of the type belonging to the family of anthracyclines, taxoids or camptothecins or of the type belonging to the family of peptides such as leuprolide or cyclosporine. and their mixtures
- a small molecule is especially a small non-protein molecule, for example, free of amino acids.
- the PA is advantageously chosen from at least one of the following families of active substances: alcohol abuse treatment agents, agents for treating Alzheimer's disease, anesthetics, acromegaly treatment agents, analgesics, anti-asthmatics, allergy treatment agents, anti-cancer agents, anti-inflammatories, anticoagulants and antithrombotics, anticonvulsants, antiepileptics, antidiabetics, antiemetics, antiglaucoma, antihistamines, antiinfectives, antibiotics, antifungals, antivirals, antiparkinsonians, anti-cholinergics, antitussives, carbonic anhydrase inhibitors, cardiovascular agents, lipid-lowering agents, anti-arrhythmics, vasodilators, anti-anginal medications, antihypertensives, vasoprotectants, cholinesterase inhibitors, dice central nervous system
- the mass fraction of PA not associated with micrometric particles [non-associated PA] in% by weight is such that: o [PA not associated] ⁇ 1 o preferably [PA not associated] ⁇ 0.5.
- 2 nd aspect of the invention the process for obtaining the microparticles by atomization of a solution or a colloidal suspension of PO containing PA.
- the PO contained in the solution or the colloidal suspension intended to be atomized is at least partly in the form of PO nanoparticles having a size, measured in the Tl test, of less than 500 nm. preferably between 10 and 300 nm, and more preferably still between 10 and 100 nm.
- the concentration of PO in the solution or the colloidal suspension to be atomized is, for example, between 5 mg / ml and 100 mg / ml, preferably between 10 mg / ml and 40 mg / ml.
- the PA / PO combination is carried out before or during the atomization step.
- the PO or PA may be in solid form (preferably a powder) or in the form of a liquid suspension.
- the PO polymer microparticles associated with at least one active principle (PA) are dispersed in a substantially aqueous liquid medium, said medium preferably containing a dispersion means M1, and the dispersion obtained is freeze-dried.
- PA active principle
- the lyophilisate thus obtained has the advantage of facilitating the preparation of liquid formulations based on microparticles (3 rd aspect of the invention described below) because it lyophilisate disperses rapidly in the useful reconstituting liquid for preparing the above liquid formulations .
- the dispersion means M1 is chosen from the group consisting of: multivalent ions whose polarity is opposite to the polarity of the ionizable groups of the PO polymer and which are contained in the aqueous continuous phase; ii- at least one hydrophilic compound (preferably usable for an injectable preparation) added to the suspension / PO solution to be atomized and thus contained in the atomized PO / PA microparticles; iii- at least one coating of the microparticles with at least one film of at least one hydrophilic compound (preferably used for an injectable preparation); iv- change of pH; v- and combinations of at least two of the means (i) to (iv); the means (i) being particularly preferred.
- liquid dispersion medium it may contain the same additives as those described for the reconstitution liquid defined below.
- Liquid Formulations based microparticles obtained by spray-drying a solution or a colloidal suspension of PO containing PA.
- the formulation according to the invention may be a liquid pharmaceutical form for the prolonged release of PA comprising a low viscosity colloidal suspension, based on PO microparticles associated with at least one PA, these microparticles being those as defined above or those obtained by the process also as defined above and in the examples infra.
- the qualifiers "low” or “very low viscosity” correspond, advantageously, to a dynamic viscosity at 20 ° C. of less than or equal to 1000 mPa.s.
- the dynamic viscosity of the formulation measured at 20 ° C, for a shear rate of 1000 s -1 , is preferably less than or equal to 500 mPa ⁇ s, preferably between 2 and 200 mPa ⁇ s. for example, between 1, 0 and 100 mPa.s, or between 1, 0 and 50 mPa.s.
- the reference measurement for the dynamic viscosity can be carried out, for example, at 20 ° C. using an AR1000 rheometer (TA Instruments) equipped with a cone-plane geometry (4 cm, 2 °). Viscosity v is measured for a shear rate of 10 s * 1 .
- This low viscosity makes the formulations of the invention easily injectable parenterally, particularly mucosally, subcutaneously, intramuscularly, intradermally, intraperitoneally, intracerebrally or into a tumor.
- the formulation according to the invention can also be administered orally, nasally, pulmonary, vaginal or ocular, among others.
- the viscosity of the liquid formulations of the invention is low both at injection temperatures corresponding to ambient temperatures, for example between 4 and 30 ° C, than at physiological temperature.
- dry microparticles formed by atomization of amphiphilic PO may further be readily redispersed to form low viscosity suspensions or microparticulate solutions.
- said formulation comprises a means M2 for dispersing the microparticles of PO / PA.
- M2 of dispersion may differ depending on the nature of the continuous phase (that is to say the reconstitution liquid) of the suspension forming part of the formulation.
- the continuous phase of the suspension is essentially aqueous
- the continuous phase of the suspension is an essentially organic phase miscible with water.
- the continuous phase of the suspension is an essentially organic phase immiscible with water.
- the continuous phase of the suspension is an essentially organic phase miscible or not with water.
- continuous essentially aqueous phase is meant, for example, a liquid containing at least 60% by weight of water.
- essentially organic continuous phase is meant, for example, a liquid containing at least 60% by weight of organic phase.
- dispersion means M2 is for example chosen from the group consisting of: multivalent ions whose polarity is opposite to the polarity of the ionizable groups PO polymer and which are contained in the aqueous continuous phase; ii- at least one hydrophilic compound (preferably usable for an injectable preparation) added to the suspension / PO solution to be atomized and thus contained in the atomized PO / PA microparticles; iii- at least one coating of the microparticles with at least one film of at least one hydrophilic compound (preferably used for an injectable preparation); iv- change of pH; v- and combinations of at least two of the means (i) to (iv); the means (i) being particularly preferred.
- the dispersion means M2 is for example chosen from the group consisting of: multivalent ions whose polarity is opposite to the polarity of the ionizable groups PO polymer and which are contained in the aqueous continuous phase; ii- at least one hydrophilic compound (
- the dispersion means M2 may comprise multivalent ions whose polarity is opposite to the polarity of the ionizable groups GI (at least partially ionized) of the polymer PO and which are introduced into the phase aqueous continuous, when reconstituting the suspension / solution that forms the suspension.
- multivalent ions denotes, for example, divalent ions, trivalent ions, tetravalent ions and mixtures of these ions.
- the multivalent ions are multivalent cations, preferably divalent cations, more preferably still selected from the group consisting of: Mg + , Ca + , Zn + , Fe + , Cu 2+ or mixtures thereof, or trivalent cations, more preferably still selected from the group consisting of: Al 3+ , Fe 3+ or mixtures thereof.
- the formulation according to the invention contains monovalent ions (eg cations), possibly active in the aggregation of nanoparticles into microparticles.
- multivalent ions are brought into the formulation of the invention, preferably in the form of aqueous saline solution (organic or inorganic), for example a solution of sulfate, chloride, acetate, gluconate or glutamate (or other anionic amino acid) of cations. multivalent.
- This multivalent ion-dispersing means M2 is more preferable in the case where the amphiphilic PO (for example a (co) polyamino acid) is relatively hydrophilic.
- the amphiphilic PO for example a (co) polyamino acid
- the dispersion means M2 can essentially comprise:
- At least one hydrophilic compound (preferably used for an injectable preparation) added to the suspension / PO solution to be atomized and thus contained in the atomized PO / PA microparticles;
- M2 of dispersion can be incorporated in the formulation according to several modes.
- At least one hydrophilic compound chosen from those used in an injectable preparation preferably selected from the group comprising:
- ⁇ amino acids eg lysine, arginine, glycine
- Polyalkylene glycols preferably polyethylene glycols
- Copolyalkylene glycols preferably ethylene glycol-propylene glycol copolymers (of the Poloxamer, Pluronic or Lutrol type);
- Cellulosic polymers and their derivatives preferably carboxyalkylcelluloses (eg carboxymethylcelluloses) or alkylcelluloses (eg methylcelluloses);
- Polyols such as propylene glycol or glycerol
- Nitrogen-containing (co) polymers preferably those contained in the group comprising polyacrylamides, poly-N-vinylamides, polyvinylpyrrolidones (PVP) and polyvinylvinyl lactams;
- the microparticles are coated with at least one layer of at least one hydrophilic compound as defined above.
- the hydrophilic compound preferably comprises at least one hydrophilic polymer chosen from hydrophilic compounds as defined above.
- the M2 (ii) dispersion means based on at least one hydrophilic compound has proved particularly suitable for amphiphilic POs having a sufficiently high hydrophobicity, for example a level of GH groups greater than or equal to 10 mol% for a PO constituted by at least one polyamino acid.
- the coating (average M2 (iii)) of the microparticles with such a layer of hydrophilic and biocompatible compound can be, for example, carried out by two successive atomizations; the second atomization, carried out on a suspension of particles in a solvent immiscible with said microparticles, can contribute to facilitating the dispersion of these particles.
- M2 (iii) of dispersion by hydrophilic coating of the microparticles, allows the suspension of microparticles to remain intact and stable for at least a few days, which makes its handling easier.
- the combination of a means M2 (ii) or (iii) for dispersing the microparticles based on hydrophilic compound (s) and a divalent ion-based dispersion medium M2 (i), contained in the aqueous phase during the reconstitution of the formulation allows accelerated dispersion.
- the aqueous continuous phase or the hydrophilic coating may also contain at least one injectable surfactant such as
- Tween® 80 a lecithin, phosphatidylethanolamine, phosphatidylserine or a polyoxypropylene-polyoxyethylene copolymer (trade name: Poloxamer, Pluronic, Lutrol).
- Another dispersible means that can be envisaged according to the invention consists of a means of dispersion by pH change, preferably before atomization.
- This type of means has proved suitable especially in the case where the amphiphilic PO (for example polyamino acid) is a compound bearing ionizable functions and is otherwise very hydrophilic, that is to say comprising, for example, less than 10 mol% of hydrophobic groups GH.
- this pH changing dispersion means (iv) before atomization is applied to the suspension / PO solution just before the atomization.
- M2 (ii) or (iii) of dispersion based on hydrophilic compound preferably by coating M2 (iii) microparticles with at least one hydrophilic polymer.
- the dispersing means consists of this organic phase which is miscible with water.
- This phase can thus contain, for example, ethanol, N-methylpyrrolidone, dimethylsulfoxide, isopropanol, glycerol or glycofurol (tetrahydrofurfuryl alcohol polyethylene glycol ether).
- the dispersing means comprises a lipophilic liquid, whose melting temperature is preferably less than or equal to 15 C, contained in the continuous organic phase immiscible with water.
- the lipophilic liquid comprises at least one mixture of triglycerides of saturated fatty acids or at least one vegetable oil or at least one lipid or at least one lipid derivative or at least one fatty acid or at least one acid derivative.
- the lipophilic liquid comprises:
- At least one vegetable oil preferably soybean oil, palm oil, linseed oil, cottonseed oil, sesame oil, sunflower oil, peanut, • at least one lipid, preferably liquid lecithin, synthetic or natural vitamin E;
- At least one lipid derivative preferably arachidoylphosphatidylcholine and stearoylphosphatidylcholine, At least one fatty acid, preferably oleic acid, myristic acid, palmitic acid, stearic acid and their salts;
- At least one fatty acid derivative preferably a mono-, di- or triglyceride derivative, ethyl oleate, lauryl lactate, glyceryl stearate, sorbitan palmitate, sorbitan stearate, sorbitan monoleate, polysorbate;
- the triglyceride derivatives of fatty acids are particularly preferred, in particular a mixture of triglycerides of saturated C 8 -C 0 0 fatty acids derived from coconut oil, for example that marketed under the name Miglyol 812 by Sasol) .
- Other long-chain fatty acid triglycerides that can be used include vegetable oils such as soybean oil, palm oil, linseed oil, cottonseed oil, sesame oil, and the like. , sunflower oil or peanut oil.
- Atomized PO / PA powders disperse readily into this water-immiscible organic phase to give stable suspensions of microparticles which retain their integrity for several days and are, therefore, again easily manipulable. This dispersion is particularly rapid without the need to add other means (s) of dispersion, even if this possibility is possible.
- the dispersing means comprises a coating of the microparticles with at least one film-forming coating compound (preferably used for an injectable preparation).
- the film-forming compound comprises at least one hydrophobic polymer chosen from the group comprising polylactides, polyglycolides, poly (lactide-co-glycolide), polyorthoesters, polyanhydrides, polyhydroxybutyric acids and polycaprolactones. polyalkylcarbonates, water-insoluble PO polymers, their derivatives and mixtures thereof.
- the film-forming coating compound is of lipidic nature and has a melting point of preferably greater than or equal to 15 ° C. and comprises at least one mixture of saturated fatty acid triglycerides or at least one vegetable oil. or at least one lipid or at least one lipid derivative or at least one fatty acid or at least one fatty acid derivative or a mixture of these products.
- the organic continuous phase for example hydrophobic, or hydrophobic coating bit (s) may also contain at least one injectable surfactant such as Tween ® 80, lecithin, phosphatidylethanolamine, phosphatidylserine or a polyoxypropylene-polyoxyethylene copolymer (trade name: Poloxamer, Pluronic, Lutrol).
- injectable surfactant such as Tween ® 80, lecithin, phosphatidylethanolamine, phosphatidylserine or a polyoxypropylene-polyoxyethylene copolymer (trade name: Poloxamer, Pluronic, Lutrol).
- the injectable formulation comprises other additives, on the one hand those hereafter referred to as "excipients / stabilizers", and on the other hand conventional excipients.
- excipients / stabilizers may be selected from the group consisting of:
- Polyalkylene glycols preferably polyethylene glycols; Copolyalkylene glycols, preferably ethylene glycol-propylene glycol copolymers (of the Poloxamer, Pluronic or Lutrol type);
- Cellulosic polymers and their derivatives preferably carboxyalkylcelluloses (eg carboxymethylcelluloses) or alkylcelluloses (eg methylcelluloses);
- sorbitan esters of fatty acid preferably polyoxyalkylene (eg ethylene) glycol esters and at least one acid (eg oleic acid), of the Tween type, (or polysorbate);
- Polyols such as propylene glycol or glycerol; -> gelatin preferably hydrolysed; nitrogen-containing (co) polymers, preferably in the group comprising polyacrylamides, poly-vinyl-vinylamides, polyvinylpyrrolidones (PVP) and poly-N-vinyl-lactams;
- PVA polyvinyl alcohols
- One of the excipients (stabilizers) preferred according to the invention is formed by nanoparticles of at least one PO polymer, identical or different (preferably identical) from that constituting the microparticles.
- the amount of excipient / stabilizer used in the formulation is preferably between 0.01 and 10% by weight, and more preferably between 0.1 and 5% by weight.
- the stabilizers comprising nanoparticles
- they are advantageously used in the formulation in a proportion of 1.5 to 3.5% by weight, for example 2.0 to 3.0 ( ⁇ 2.5)% by weight.
- the reconstitution liquid used in the preparation of the formulation according to the invention may comprise, for example: at least one buffer or at least one injectable salt (phosphate buffer, citrate buffer, chloride of sodium) in concentration for example between 0.001 M and 0.1 M, preferably between 0.005 M and 0.02 M, this buffer or injectable salt for adjusting the pH of the solution; at least one injectable surfactant, preferably of the polysorbate type, such as
- the reconstitution liquid may further contain densifying agents such as saccharides, ie e.g. sucrose, D-mannitol or trehalose in concentrations of between 0.1% and 10%, preferably between 0.5 and 5%.
- densifying agents such as saccharides, ie e.g. sucrose, D-mannitol or trehalose in concentrations of between 0.1% and 10%, preferably between 0.5 and 5%.
- the reconstitution solution may also contain an injectable viscosifying polymer selected from the group consisting of polysaccharides, synthetic polymers (eg, sodium carboxymethylcellulose), polyvinyl alcohol, polyvinylpyrrolidone, polyalkylene glycols (e.g. polyethylene glycols) and mixtures thereof.
- amphiphilic PO eg polyamino acid
- ad hoc means of reconstitution thus makes it possible to meet the double objective which is to be able to obtain pharmaceutical formulations both stable and easily dispersible to allow their parenteral injection.
- the other conventional excipients which can be added to the suspension / solution to be atomized or to the formulation according to the invention are, for example, antimicrobials, buffers, antioxidants, or isotonicity adjusting agents known to those skilled in the art.
- antimicrobials for example, antimicrobials, buffers, antioxidants, or isotonicity adjusting agents known to those skilled in the art.
- buffers for example, buffers, antioxidants, or isotonicity adjusting agents known to those skilled in the art.
- isotonicity adjusting agents known to those skilled in the art.
- formulation according to the invention is preferably pharmaceutical, this does not exclude cosmetic, dietary or phytosanitary formulations comprising at least one PO as defined above and at least one PA.
- the PO / PA microparticles and the essentially aqueous reconstitution liquids, the essentially organic and water miscible reconstitution liquids and the essentially water-immiscible organic liquids are defined above.
- the PO / PA microparticles and the essentially aqueous reconstitution liquids, the essentially organic and water miscible reconstitution liquids and the essentially water-immiscible organic liquids are defined above.
- This formulation for the sustained release of PA comprises a dry powder form for inhalation and pulmonary administration based on PO / PA microparticles defined above.
- the present invention also relates to solid products derived from the microparticles of PO according to the invention.
- these derived products may in particular be constituted by powders, gels, implants or films, among others.
- the invention relates to products derived from the formulation according to the invention, taken as such, regardless of their method of production.
- the invention also relates to a method of therapeutic treatment consisting essentially of administering a therapeutically effective amount of the formulation as described herein, parenterally, in particular mucosally, subcutaneously, intramuscularly, intradermally, intraperitoneally. , intracerebral or in a tumor.
- the formulation according to the invention can also be administered orally, nasally, pulmonary, vaginal or ocular, among others.
- this method of therapeutic treatment consists in administering the formulation as described above by parenteral injection: subcutaneously, intramuscularly, intradermally, intraperitoneally, intracerebrally or in a tumor, preferably so that it forms a deposit at the injection site.
- the solution was cooled to 15 ° C and successively 2.5 g of D, L-alpha-tocopherol (> 98%, obtained from Fluka ®), previously solubilized in 8 ml of DMF, 280 mg of 4-dimethylaminopyridine dissolved beforehand in 1 ml of DMF and 1.6 g of diisopropylcarbodiimide previously solubilized in 6 ml of DMF.
- the precipitated polymer is then recovered by filtration, washed with 0.1 N hydrochloric acid, water and with diisopropyl ether.
- the polymer is then dried in an oven under vacuum at 40 ° C. A yield of the order of 90% is obtained.
- the molar mass measured by size exclusion chromatography is 15500 relative to a polyoxyethylene standard.
- the grafted tocopherol level, estimated by proton NMR spectroscopy, is 5.1 mol%.
- a suspension of nanoparticles of the polymer in water is obtained by solubilizing it in water and adjusting the pH to 7 ⁇ 1 (neutralization of the carboxylates).
- EXAMPLE 2 SYNTHESIS OF AN AMPHIPHILE PO-B POLYMER
- Example 2 is adapted from Example 1, aiming for a grafting rate of 20%
- the mixture is left for 14 hours at room temperature.
- the solution is filtered through a 0.2 ⁇ m sterilizing filter.
- the solution is atomized on a spray-drying apparatus of B ⁇ chi B290 type.
- the liquid solution is aspirated at a rate of 5 ml / min and nebulized through a spray nozzle fed with nitrogen (700 kPa - 900 1 / h).
- the suction flow rate (drying air) is 40 m 3 / h.
- the inlet temperature is maintained at 90 ° C., which induces under these conditions a temperature at the outlet of 45 ° C.
- the HFN assay by HPLC is identical to that of the solution before atomization. No degraded form is detected.
- the PO polymer and interferon solution is prepared in the same manner as in Example 3. 0.9 g of polysorbate 80 are added to the solution before atomization.
- the IFN assay by HPLC is identical to that of the solution before atomization. No degraded form is detected.
- the PIFN assay by HPLC is identical to that of the solution before atomization. No degraded form is detected.
- a powder of dry microparticles of PO-A and IFN polymer is obtained from a PO-A / IFN mixture according to the protocol used in Example 3.
- the IFN assay by HPLC is identical to that of the solution before atomization. No degraded form is detected.
- the PIFN assay by HPLC is identical to that of the solution before atomization. No degraded form is detected.
- EXAMPLE 8 PREPARATION OF DRY MICROMETRIC PARTICLES OF POLYMER PO-A CONTAINING HGH
- a recombinant human growth hormone solution (concentration 3.9 mg / g) are thawed for 90 min at 25 ° C. and concentrated approximately 6 times by frontal ultrafiltration on an exclusion limit membrane of 10 kD until to obtain a concentration of 24 mg / g (controlled by HPLC).
- the HPLC assay of hGH is identical to that of the solution before atomization. No degraded form is detected.
- the mixture containing 20 mg / g of PO polymer and 1.25 mg / g of IL-2 is left overnight at room temperature and then filtered through a 0.2 ⁇ m sterilizing filter.
- the IL-2 assay by HPLC is identical to that of the solution before atomization. No degraded form is detected.
- the solution is then atomized on a spray-drying apparatus of B ⁇ chi B290 type.
- the liquid solution is aspirated at a rate of 5 ml / min and nebulized through a spray nozzle fed with nitrogen (700 kPa - 900 1 / h).
- the suction flow rate (drying air) is 40 m 3 Vh.
- the inlet temperature is maintained at 120 ° C., which induces under these conditions a temperature at the outlet of 70 ° C.
- the insulin assay by HPLC is identical to that of the solution before atomization. No degraded form is detected.
- the size of the microparticles is measured according to the TO test and the stability according to the S 1 test.
- the evaluation of the degradation of the protein is carried out by HPLC by comparing a chromatogram of the formulation before and after atomization.
- Atomization is a method that can degrade the protein. HPLC analysis shows that no form of degradation is observed by comparing the chromatograms before and after atomization.
- the atomization of a protein in the presence of an amphiphilic polyamino acid leads to microparticles that are stable over time and does not induce degradation of the protein.
- powders can be used in solid form (inhalation, needleless injection by a pressure gun for example) or in the form of an injectable suspension after reconstitution in a suitable medium.
- EXAMPLE 12 SUSPENSION RECONSTITUTION FROM THE POWDERS OF EXAMPLES 3 TO 10
- the samples are then evaluated by carrying out the following steps: dispersion in one of the abovementioned media transfer into a syringe and injection through a 25G syringe
- the suspension is considered to have good properties if at least 80% is recovered by suction / injection through a 25G needle.
- EXAMPLE 13 VISCOSITY MEASUREMENT OF THE RECONSTITUTED FORMULATIONS
- a dispersion of the powders at 30 mg / ml in the media B and C of the preceding examples (except for 5 in the medium B) give stable, low-viscosity suspensions; in medium B, the viscosities measured are all less than 10 mPa.s and in medium C, the viscosities are all of the order of 30 to 40 mPa.s.
- a composition of the same nanoparticulate polymers according to the prior art can not be obtained at this concentration (30 mg / mL) in the acceptable viscosity values ( ⁇ 100 mPa.s).
- the particles are first prepared as described in Example 3.
- the atomization step is performed under aseptic conditions and the particles are recovered in a sterile container.
- the particles are recovered and redispersed under aseptic conditions in an aqueous solution of MgCl 2 0.10 M.
- the amount of MgCl 2 solution added is adjusted so that the polymer concentration PO-A in the suspension is approximately 40 mg / ml.
- the pH is adjusted to 6.5 by adding 1N sodium hydroxide. Lyophilization
- the suspension is divided into Lyoguard ® containers to keep the suspension sterile during lyophilization: the containers are then sterilized lyophilized during a 72 h cycle on a laboratory freeze-dryer (Christ benchtop module, Osterode, Germany). The powder is sterilely distributed in vials before use.
- EXAMPLE 15 COMPARISON OF THE RECONSTITUTION OF THE POWDERS OF MICROPARTICLES OBTAINED FROM EXAMPLE 3 AND THOSE OF EXAMPLE 14
- the volumes of reconstituted suspension are identical in both cases (about 1 ml) and the reconstitution vials are identical (3 ml glass vials).
- the amounts of powder are adjusted so that the two suspensions finally contain 40 mg / ml of polymer and 0.5 mg / ml of IFN- ⁇ -2b.
- the powder of Example 3 is reconstituted in an aqueous solution of MgCl 2 0.1 M while the powder of Example 14 (which already contains Mg 2+ ions) is reconstituted in pure water.
- the bottles are stirred manually. While the powder of Example 3 requires at least 15 min to redisperse, the dispersion is faster for the powder of Example 14 and in less than 5 min, a homogeneous suspension is obtained. A magnetic bar is then inserted into the flasks and the two flasks are shaken in an identical manner for 1 h.
- the characteristics of the two suspensions are compared: the particle size and the viscosity of the two suspensions are similar.
- EXAMPLE 16 PHARMACOKINETICS OF IFN IN THE DOG AFTER SUB-CUTANEOUS INJECTION OF A FORMULATION BASED ON AMPHIPHILIC POLYAMINOACIDES IN THE MICROPARTICULAR FORM Eight naive Beagle dogs (weight of 9 ⁇ 0.6 kg) were treated with the following formulations:
- IR-IFN IR for immediate release, ie immediate release
- PCGen a recombinant human interferon solution
- the particles of the formulation 1 are prepared according to Example 14 from the same batch of interferon PCGen: the lyophilized powder is resuspended in water sterilely (in a laminar flow hood) according to a process similar to that described in example 15.
- C max is the maximum serum concentration in IFN
- T> 50 ⁇ g / ml is the time when the serum concentration of IFN is greater than
- AUC represents the area under the serum IFN concentration versus time curve
- RBA represents bioavailability compared to an Immediate Release formulation
- T 50 o / oauc represents the time required to release 50% of released PIFN in total.
- the IFN IR has a rapid release profile with a peak serum concentration of 25.2 ⁇ 0.4 ng / mL achieved after a median time of 5 h (range: 3-5 h).
- the circulating IFN is no longer quantifiable beyond 24 hours.
- Formulation 1 provides a major change in the pharmacokinetic profile of IFN, with very slow release, and a peak serum concentration of 0.5 ⁇ 0.2 ng / mL (50 times lower than that of the IR form) reached after a median time of 60 h (range: 48 - 96 h).
- the general pattern of pharmacokinetics is a flat profile pseudoplatter.
- the circulating IFN level returns to an unquantifiable concentration between 192 h and 240 h (8 and 10 days).
- the T 5 o % aUc is about 20 times higher than that of the IFN IR.
- EXAMPLE 17 PHARMACOD YNAMIE OF INSULIN IN DOGS AFTER SUBCUTANEOUS INJECTION OF A FORMULATION BASED ON AMPHIPHILIC POLYAMINO ACIDS IN MICROP ARTICULAR FORM
- Lantus ® is a modified insulin analog (insulin glargine - Sanofi-Aventis).
- the modification of two amino acids on the primary structure of human insulin gives Lantus ® extended release properties over a 24 hour period via in situ precipitation.
- a group of 6 healthy Beagle dogs (weight of 11.4 ⁇ 1 kg) were treated with the Lantus formulation in a 2-period crossover trial and a group of 8 healthy Beagle dogs (weight 1 1, 8 ⁇ 1 kg) was treated with Formulation 2, two by two, in a 4-period crossover trial.
- the summary table of treatments is summarized below:
- the particles of the formulation 2 are prepared according to Example 10 by aiming at a ratio of 30 mg of PO polymer for 3.5 mg (100 IU) of insulin.
- the formulation is prepared by dispersing the atomized powder in 0.1 M MgCl 2 and magnetic stirring of the suspension for 1 h.
- the pH of the formulation is 6.2 and the osmolality is 348 mOsm.
- the blood glucose is measured by enzymatic method (hexokinase) on an automaton of biochemical blood tests (Advia 1650, Bayer Diagnostics).
- the analysis of pharmacodynamic results is performed on the percentage of basal glucose as a function of time.
- the pharmacodynamic data are grouped in the following table:
- Area Percent Glycemia Curve represents the area between the basal blood glucose (100%) and the curve representing the evolution of blood glucose
- - T 50 % APGC represents the time required to obtain 50% of the APGC 0-36I1 .
- the administration of the Lantus ® reference leads to a rapid decrease in blood glucose levels in the first hour.
- the hypoglycemic action of insulin glargine is then maintained over a period of between 18 and 36 hours (return of blood glucose to basal level after 30 hours on average).
- the duration of action of the formulation 2 is clearly greater than that of the long-acting reference Lantus ® . This is illustrated by an average value of T50% APGC higher for formulation 2.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0653191A FR2904219B1 (fr) | 2006-07-28 | 2006-07-28 | Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant |
PCT/EP2007/006722 WO2008025425A1 (fr) | 2006-07-28 | 2007-07-30 | Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2049085A1 true EP2049085A1 (fr) | 2009-04-22 |
Family
ID=37814390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07801468A Withdrawn EP2049085A1 (fr) | 2006-07-28 | 2007-07-30 | Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2049085A1 (fr) |
JP (1) | JP5302197B2 (fr) |
KR (1) | KR101407033B1 (fr) |
CN (1) | CN101568328B (fr) |
BR (1) | BRPI0714943A2 (fr) |
CA (1) | CA2661567C (fr) |
FR (1) | FR2904219B1 (fr) |
IL (1) | IL196426A (fr) |
MX (1) | MX2009000951A (fr) |
WO (1) | WO2008025425A1 (fr) |
ZA (1) | ZA200900929B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2934161B1 (fr) * | 2008-07-28 | 2010-09-17 | Flamel Tech Sa | Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules. |
FR2940619B1 (fr) * | 2008-12-31 | 2012-02-10 | Flamel Technologies Sa | Composition comprenant un actif de solubilite aqueuse faible ou moyenne |
FR2954325B1 (fr) | 2009-12-23 | 2012-02-03 | Flamel Tech Sa | Polymere amphiphile fonctionnalise par la methionine |
JP4829351B2 (ja) * | 2010-02-05 | 2011-12-07 | ナノキャリア株式会社 | 易崩壊型ポリマーミセル組成物 |
CN102232932B (zh) * | 2010-04-27 | 2013-06-05 | 重庆莱美药业股份有限公司 | 果胶-阿霉素轭合物的冻干制剂及制备方法 |
CN102657843A (zh) * | 2012-06-05 | 2012-09-12 | 云南民族大学 | 抗菌肽组合物及其制备方法 |
CN103483583B (zh) * | 2013-09-24 | 2015-11-18 | 昆明理工大学 | 一种ε-聚赖氨酸的制备方法 |
CA2944768C (fr) | 2014-04-03 | 2022-08-30 | Biondvax Pharmaceuticals Ltd. | Compositions de polypeptides multimeres-multi-epitopes de grippe et leur production |
EP3212212B1 (fr) | 2014-10-31 | 2020-09-23 | Monash University | Formulation de poudre |
KR101891715B1 (ko) * | 2016-01-15 | 2018-08-27 | 연세대학교 산학협력단 | 바이러스 감염의 치료용 폴리아미노산 기반의 생체환경 감응형 나노입자 |
WO2018025699A1 (fr) | 2016-08-02 | 2018-02-08 | 日本化薬株式会社 | Dérivé de polymère du type à ciblage actif, composition contenant ledit dérivé de polymère, et utilisations dudit dérivé de polymère et de ladite composition |
CN110483785B (zh) * | 2019-07-01 | 2020-05-19 | 中山大学 | 一种三嵌段聚合物、载药纳米胶束、纳米药物及其制备方法和应用 |
CN110343245B (zh) * | 2019-07-16 | 2021-09-28 | 天津大学 | 一种ε-聚赖氨酸-接枝-疏水氨基酸-接枝-海藻糖的糖肽及制备方法 |
CN112553759A (zh) * | 2020-11-30 | 2021-03-26 | 福建凤竹纺织科技股份有限公司 | 一种多功能海藻纤维针织面料 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4002736A1 (de) * | 1990-01-31 | 1991-08-01 | Hoechst Ag | Biologisch abbaubare polymere, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe |
US5250293A (en) * | 1991-04-22 | 1993-10-05 | Gleich Gerald J | Method for the treatment of hypersensitivity diseases by administration of anionic polymers |
GB9221329D0 (en) * | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
DE4407898A1 (de) * | 1994-03-09 | 1995-09-14 | Hoechst Ag | Nanopartikel, enthaltend einen Wirkstoff und ein Polyketalweinsäureamid, Verfahren zu ihrer Herstellung und Verwendung derselben |
PL200954B1 (pl) * | 1999-01-18 | 2009-02-27 | Lg Life Sciences | Lipofilowe mikrocząsteczki zawierające lek proteinowy lub peptydowy i preparat zawierający te mikrocząsteczki |
FR2814951B1 (fr) * | 2000-10-06 | 2003-01-17 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs hydrophiles (insuline) et leur mode de preparation |
US20050013867A1 (en) * | 2001-10-19 | 2005-01-20 | Lehrman S. Russ | Use of proton sequestering agents in drug formulations |
FR2862536B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
FR2862535B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques |
FR2862541B1 (fr) * | 2003-11-21 | 2007-04-20 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques |
-
2006
- 2006-07-28 FR FR0653191A patent/FR2904219B1/fr not_active Expired - Fee Related
-
2007
- 2007-07-30 MX MX2009000951A patent/MX2009000951A/es active IP Right Grant
- 2007-07-30 JP JP2009525938A patent/JP5302197B2/ja not_active Expired - Fee Related
- 2007-07-30 WO PCT/EP2007/006722 patent/WO2008025425A1/fr active Application Filing
- 2007-07-30 EP EP07801468A patent/EP2049085A1/fr not_active Withdrawn
- 2007-07-30 CN CN2007800318934A patent/CN101568328B/zh not_active Expired - Fee Related
- 2007-07-30 BR BRPI0714943-3A patent/BRPI0714943A2/pt not_active IP Right Cessation
- 2007-07-30 ZA ZA200900929A patent/ZA200900929B/xx unknown
- 2007-07-30 KR KR1020097004345A patent/KR101407033B1/ko not_active IP Right Cessation
- 2007-07-30 CA CA2661567A patent/CA2661567C/fr active Active
-
2009
- 2009-01-11 IL IL196426A patent/IL196426A/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO2008025425A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2007291577A1 (en) | 2008-03-06 |
WO2008025425B1 (fr) | 2008-05-02 |
IL196426A (en) | 2014-07-31 |
FR2904219B1 (fr) | 2010-08-13 |
FR2904219A1 (fr) | 2008-02-01 |
CN101568328A (zh) | 2009-10-28 |
JP2009544759A (ja) | 2009-12-17 |
ZA200900929B (en) | 2010-06-30 |
IL196426A0 (en) | 2009-09-22 |
WO2008025425A1 (fr) | 2008-03-06 |
BRPI0714943A2 (pt) | 2013-05-21 |
KR101407033B1 (ko) | 2014-06-20 |
CN101568328B (zh) | 2012-09-05 |
MX2009000951A (es) | 2009-02-04 |
WO2008025425A9 (fr) | 2008-06-12 |
CA2661567C (fr) | 2016-09-20 |
CA2661567A1 (fr) | 2008-03-06 |
KR20090054976A (ko) | 2009-06-01 |
JP5302197B2 (ja) | 2013-10-02 |
WO2008025425A8 (fr) | 2009-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2661567C (fr) | Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant | |
EP2043600B1 (fr) | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques | |
US20080102128A1 (en) | Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them | |
USRE46686E1 (en) | Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications | |
WO2005051416A1 (fr) | Formulations pharmaceutiques pour la libération prolongée de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques | |
EP2155164A1 (fr) | Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif | |
WO2003090727A1 (fr) | Suspension colloidale de particules submicronique de vectorisation de principes actifs et leur mode de preparation | |
EP1684792B1 (fr) | Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques | |
WO2008135561A1 (fr) | Particules a base de polyelectrolytes et de principe actif a liberation modifiee et formulations pharmaceutiques contenant ces particules | |
FR2862541A1 (fr) | Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques | |
FR2975301A1 (fr) | Composition comprenant un interferon alpha |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090126 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CONSTANCIS, ALAIN Inventor name: CHAN, YOU-PING |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CHAN, YOU-PING Inventor name: CONSTANCIS, ALAIN |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20130116 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FLAMEL IRELAND LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170523 |